Intas Acquires Brussels-Based Prothya Biosolutions
A Brussels-based biopharmaceutical company focusing on extracting antibodies and other raw materials from donor blood plasma has been acquired by a subsidiary of the Indian multinational Intas, reports 24brussels.
Prothya Biosolutions, which evolved from a division of the Red Cross, operates a factory in the Netherlands and plasma centers in Hungary. The acquiring entity, Accord Plasma, is a family-owned company primarily involved in the production of generic medications while also engaging in plasma-derived products.
This acquisition aims to position Intas within the rapidly expanding plasma-derived medicine market, which is currently dominated by a select few multinational corporations.
Global Platform Established
Intas and Accord chair Binish Chudgar expressed optimism regarding the acquisition, stating, “We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions.”
He added, “Combined with our fractionation capabilities in India, this positions us to create a truly global plasma platform — serving patients worldwide with critical, often under-prescribed, therapies.”
Prothya Biosolutions has faced challenges in recent years, particularly due to operational difficulties in the Netherlands. Last year, the company’s turnover declined by 12 percent, totaling 267.9 million euros. The company employs 1,200 individuals, with 350 of them located in Belgium.
Previously owned by the Dutch blood bank Sanquin, Prothya was acquired in 2021 by a consortium led by Fortissimo Capital, an Israeli investment fund known for its success with SodaStream.
